Table 4.
Viral vector vaccine candidates for COVID-19
| Viral Vector-Non -replicating (Phase 3 and above) Vaccine candidates (Source: WHO as per 15th October 2021) | |||||
|---|---|---|---|---|---|
| Candidate | Dose | Schedule | Route of Administration | Phase | Developer |
| ChAdOx1-S—(AZD1222) (Covishield) | 1–2 | Day 0 + 28 | Intramuscular |
Phase 4 EUCTR2021-002327-38-NL ACTRN12621000661875 |
AstraZeneca, University of Oxford |
| Recombinant novel coronavirus vaccine (Adenovirus type 5 vector) | 1 | Day 0 | Intramuscular |
Phase 4 |
CanSino Biological Inc./Beijing Institute of Biotechnology |
| Gam-COVID-Vac Adeno-based (rAd26-S + rAd5-S) | 2 | Day 0 + 21 | Intramuscular |
Phase 3 |
Gamaleya Research Institute; Health Ministry of the Russian Federation |
| DelNS1-2019-nCoV-RBD-OPT1 | 2 | Day 0 + 28 | Intranasal |
Phase-3 ChiCTR2100051391 |
University of Hong Kong, Xiamen university and Beijing Wantai Biological pharmacy |
| Ad26.COV2.S | 1–2 | Day 0 or Day 0 + 56 | Intramuscular |
Phase 4 EUCTR2021-002327-38-NL |
Janssen Pharmaceutical |